Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “buy” rating restated by Wedbush in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports. They currently have a $186.00 price target on the biotechnology company’s stock. Wedbush’s target price points to a potential upside of 63.93% from the company’s current price.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. boosted their target price on Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Zacks Investment Research upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $118.00 target price for the company in a research report on Tuesday, October 29th. BidaskClub lowered Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 12th. Morgan Stanley began coverage on Ascendis Pharma A/S in a research report on Friday, October 11th. They set an “overweight” rating and a $128.00 target price for the company. Finally, ValuEngine upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $142.75.

Shares of Ascendis Pharma A/S stock traded up $6.48 during trading on Tuesday, hitting $113.46. 773,162 shares of the company were exchanged, compared to its average volume of 302,572. The firm has a market capitalization of $4.74 billion, a P/E ratio of -30.34 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $54.67 and a 1-year high of $133.96. The firm’s fifty day moving average price is $103.68 and its 200 day moving average price is $113.01. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.59 and a quick ratio of 11.59.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.08). The company had revenue of $3.61 million for the quarter, compared to analyst estimates of $0.68 million. Ascendis Pharma A/S had a negative return on equity of 35.99% and a negative net margin of 932.52%. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -5.29 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in ASND. Price T Rowe Associates Inc. MD lifted its holdings in shares of Ascendis Pharma A/S by 53.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,178,036 shares of the biotechnology company’s stock valued at $826,551,000 after purchasing an additional 2,509,034 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Ascendis Pharma A/S by 1,024.8% during the 2nd quarter. Invesco Ltd. now owns 1,014,346 shares of the biotechnology company’s stock valued at $116,802,000 after purchasing an additional 924,169 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Ascendis Pharma A/S by 41.5% during the 2nd quarter. Westfield Capital Management Co. LP now owns 971,752 shares of the biotechnology company’s stock valued at $111,897,000 after purchasing an additional 285,207 shares in the last quarter. Camber Capital Management LP lifted its holdings in shares of Ascendis Pharma A/S by 51.2% during the 2nd quarter. Camber Capital Management LP now owns 650,000 shares of the biotechnology company’s stock valued at $74,848,000 after purchasing an additional 220,000 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Ascendis Pharma A/S by 192.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 51,484 shares of the biotechnology company’s stock valued at $5,581,000 after purchasing an additional 107,160 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: How to calculate the annual rate of depreciation

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.